Back to School: How biopharma can reboot drug development. Access exclusive analysis here
A double-blind, Danish Phase II trial in 342 cancer patients receiving highly emetogenic chemotherapy (HEC) showed that APD403
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury